Lumida
/KYMR
⌘K
Kymera Therapeutics Inc

Kymera Therapeutics Inc

KYMR
$114.96USD-1.74%-2.04 today

MARKET CAP

9.6B

P/E (TTM)

FWD P/E

DAY RANGE

$114 – $120

52W RANGE

$44
$130

AI Summary

Stalk
Sell NowMedium

KYMR is in Stage 3 distribution with active lower highs & lower lows pattern, confirming medium-term bearish bias. Short-term weakness at EMAs favors selling into rallies with price below declining 9/20 EMAs and 50 SMA, but long-term trend remains supported by the 200-day SMA. We will sell now into resistance around the 20-day EMA and prior swing highs.

  • Q2 collaboration revenue $65M, beating $32.8M estimate driven by Gilead and Sanofi milestones
  • KT-621 Phase 2b atopic dermatitis enrollment completed six months early; top-line data by year-end 2026
  • Negative profitability and earnings yield highlight inefficient capital returns
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$72.8M$46.8M$78.6M$47.1M$39.2M
YoY %+114.0%-35.7%+67.8%-40.1%-16.7%
P / Sales41.8x28.6x18.8x64.1x167.7x
EV / Sales43.2x29.6x19.7x64.6x162.7x
Gross Profit, Adj.$72.8M$46.8M$78.6M$47.1M$39.2M
YoY %+114.0%-35.7%+67.8%-40.1%-16.7%
Margin %100.0%100.0%100.0%100.0%100.0%
EV / Gross Profit43.2x29.6x19.7x64.6x162.7x
EBITDA, Adj.$-98.1M$-161.3M$-162.0M$-249.3M$-337.2M
YoY %-120.3%-64.3%-0.4%-53.9%-35.3%
Margin %-134.7%-344.4%-206.1%-529.7%-860.0%
EV / EBITDA-32.0x-8.6x-9.6x-12.2x-18.9x
EBIT$-100.5M$-161.3M$-165.5M$-261.6M$-349.4M
YoY %-117.1%-60.4%-2.7%-58.1%-33.5%
Margin %-138.0%-344.4%-210.6%-555.8%-891.1%
EV / EBIT-31.3x-8.6x-9.4x-11.6x-18.3x
Net Income$-100.2M$-154.8M$-147.0M$-223.9M$-311.4M
YoY %-83.4%-54.5%+5.1%-52.3%-39.1%
Net Margin-137.6%-330.6%-187.0%-475.6%-794.0%
EPS (GAAP)-$2.09-$2.87-$2.52-$2.98-$3.69
YoY %+33.7%-37.3%+12.2%-18.3%-23.8%